Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$3.04M (0 inflow days, 20 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 21.2% of shares outstanding.
Reported short interest has risen from 0.09% to 0.20% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | Hedge Fund | 2026/Q3 | +2,016,211 | 3.5% |
| CrossingBridge Advisors, LLC | Mutual Fund | 2026/Q3 | +750,000 | 1.7% |
| TIG Advisors, LLC | Hedge Fund | 2026/Q3 | +500,000 | 0.8% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +426,321 | 0.9% |
| Logan Stone Capital, LLC | Hedge Fund | 2026/Q3 | +370,373 | 0.6% |
| Cantor Fitzgerald Asset Management | Mutual Fund | 2026/Q3 | +363,100 | 0.6% |
| Kepos Capital LP | Hedge Fund | 2026/Q3 | +210,000 | 0.3% |
| Clear Street LLC | Private Company | 2026/Q3 | +209,534 | 0.4% |
| Karpus Management Inc. | Mutual Fund | 2026/Q3 | +190,075 | 4.4% |
| Limestone Investment Advisors LP | Mutual Fund | 2026/Q3 | +139,100 | 0.2% |
| Westchester Capital Management, LLC | Mutual Fund | 2026/Q3 | +121,791 | 1.0% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +84,900 | 2.3% |
| Arax Advisory Partners, LLC | Mutual Fund | 2026/Q3 | +65,990 | 0.1% |
| Wolverine Asset Management, LLC | Hedge Fund | 2026/Q3 | +59,931 | 2.9% |
| PenderFund Capital Management Ltd. | Mutual Fund | 2026/Q3 | +29,800 | 0.1% |
Institutional buy/sell activity by reporting period, largest moves first.
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 25 Sep 2025 | Glenn Worman | Chief Financial Officer | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Sridhar Prasad | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Catherine Do | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Myron Shulgan | Independent Director | Other Acquisition | +100,000 | – | 100,000 |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Other Disposition | -400,000 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Private Acquisition | +700,000 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Private Disposition | -7,966,667 | – | 6,708,333 | |
| 25 Sep 2025 | Drugs Made In America Acquisition II LLC | Open Market Derivative Acquisiti | +700,000 | – | 700,000 | |
| 23 Sep 2025 | Drugs Made In America Acquisition II LLC | Initial Statement of Beneficial | +0 | – | 14,375,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 126,137 | 0.2% | 3.3 |
| 31 Aug 2026 | 119,323 | 0.2% | 1.9 |
| 14 Aug 2026 | 121,957 | 0.2% | 159.6 |
| 31 Jul 2026 | 135,284 | 0.2% | 1.4 |
| 15 Jul 2026 | 46,508 | 0.1% | 1.6 |
| 30 Jun 2026 | 58,818 | 0.1% | 1.0 |
No comments yet — be the first to weigh in on DMII.